Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Donna Morrell"'
Autor:
David F. Penson, Dennis Deapen, Terri Kang Johnson, Peter C. Albertsen, Donna Morrell, Richard M. Hoffman, Ann S. Hamilton
Publikováno v:
BJU International. 107:576-584
Study Type – Therapy (cohort) Level of Evidence 2b What’s known on the subject? and What does the study add? Variation in treatment of localized prostate cancer has been shown to exist according to demographic and clinical factors, patient and pr
Autor:
Ann S. Hamilton, Steven J. Katz, Donna Morrell, Timothy P. Hofer, Meryl Leventhal, Dennis Deapen, Barbara Salem, Sarah T. Hawley
Publikováno v:
Cancer Epidemiology, Biomarkers & Prevention. 18:2022-2029
Purpose: Latinas and African-Americans with breast cancer, especially those of lower socioeconomic status and acculturation, have been underrepresented in studies assessing treatment satisfaction, decision-making, and quality of life. A study was des
Publikováno v:
Breast cancer research and treatment. 127(1)
To describe therapy and changes in therapy over time for women diagnosed with ductal carcinoma in situ (DCIS) and treated in the community setting. Women aged 20 or older diagnosed with DCIS in this study were sampled from the population-based Survei
Autor:
Ann S, Hamilton, Peter C, Albertsen, Terri Kang, Johnson, Richard, Hoffman, Donna, Morrell, Dennis, Deapen, David F, Penson
Publikováno v:
BJU international. 107(4)
To conduct an analysis of localized prostate cancer treatment in the USA between 1998 and 2002.Results from the National Cancer Institute's Patterns of Care study from 10 regional cancer registries in 1998 and 14 registries in 2002 were compared usin
Autor:
Donna Morrell, Lynn G. Ries, Vivien W. Chen, Linda C. Harlan, Mary S. Potts, Brenda K. Edwards, Christopher I. Li, Dennis Deapen, Marsha E. Reichman, Amanda I. Phipps, Xiao-Cheng Wu, Sean F. Altekruse, Jennifer L Hafterson
Publikováno v:
Cancer epidemiology, biomarkersprevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 19(1)
The clinical importance of human epidermal growth factor receptor-2 (HER2) in breast cancer is now clearly established, given that expression of this tumor marker is used to guide therapy and as a prognostic indicator. Despite its now routine evaluat